Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
The New England Journal of Medicine - 14 Jul 2021Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 ...
bamlanivimab
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 ...
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19 | Eli Lilly and Company
Eli Lilly and Company - 09 Nov 2020Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19 | Eli Lilly and Company ...
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
Nature - 22 Aug 2022Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 ...
Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product
Frontiers - 26 Jun 2024Introduction of a Capillary Gel Electrophoresis-Based Workflow for Biotherapeutics Characterization: Size, Charge, and N-Glycosylation Variant Analysis of Bamlanivimab, an Anti-SARS-CoV-2 Product ...
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination
ScienceDirect.com - 20 Jul 2021SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination ...
EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly
European Medicines Agency - 02 Nov 2021EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID-19 following withdrawal by Lilly ...
Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab
Reuters - 16 Apr 2021Lilly asks FDA to not allow lone use of COVID-19 drug bamlanivimab ...
Bamlanivimab (LY-Cov555) for the Treatment of COVID-19, USA
Clinical Trials Arena - 19 Nov 2020Bamlanivimab (LY-Cov555) for the Treatment of COVID-19, USA ...
Fig. 2 A timeline of the clinical development of bamlanivimab alone and...
ResearchGate - 03 Sep 2022Fig. 2 A timeline of the clinical development of bamlanivimab alone and... ...
Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12
Eli Lilly and Company - 03 Dec 2021Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12 ...
Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial
Nature - 26 Oct 2022Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial ...
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
The New England Journal of Medicine - 11 Oct 2022Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 ...
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19
Eli Lilly and Company - 09 Feb 2021Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19 ...
Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies | Scientific Reports
Nature - 12 Oct 2021Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies | Scientific Reports ...
Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Eli Lilly and Company - 10 Mar 2021Lilly's bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19 ...
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Eli Lilly and Company - 21 Jan 2021Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents ...
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
Eli Lilly and Company - 05 Mar 2021EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union ...
Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S.
Eli Lilly and Company - 16 Apr 2021Lilly requests revocation of emergency use authorization for bamlanivimab alone to complete transition to bamlanivimab and etesevimab together for treatment of COVID-19 in the U.S. ...
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent
Eli Lilly and Company - 26 Jan 2021New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent ...